Niagen Bioscience Inc NAGE.OQ NAGE.O is expected to show a rise in quarterly revenue when it reports results on August 6 for the period ending June 30 2025
The Los Angeles California-based company is expected to report a 24.6% increase in revenue to $28.324 million from $22.74 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.
LSEG's mean analyst estimate for Niagen Bioscience Inc is for earnings of 1 cent per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Niagen Bioscience Inc is $16.00, about 39.8% above its last closing price of $9.64
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
0.02
0.02
0.06
Beat
259.9
Dec. 31 2025
0.02
0.02
0.09
Beat
350
Sep. 30 2024
0.01
0.00
0.02
Beat
500.6
Jun. 30 2024
-0.02
-0.02
0.00
Beat
100
Mar. 31 2024
-0.02
-0.02
-0.01
Beat
40
Dec. 31 2023
-0.03
-0.03
0.00
Beat
100
Sep. 30 2023
-0.03
-0.03
-0.01
Beat
69.2
Jun. 30 2023
-0.04
-0.04
-0.03
Beat
20
This summary was machine generated August 4 at 23:15 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)